Co-Diagnostics, Inc. (CODX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Diagnosticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
CRITICAL DILUTION RISKDilution score: 87/100 (CRITICAL), 2.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 11.97% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
- Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
- Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
- Co-Diagnostics to Hold Press Conference
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Co-Diagnostics, Inc..
Full CODX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.